Skip to main content
XenonStack

Agentic AI Systems

XenonStack Blog Agentic AI in Pharma: Drug Discovery and Content

and | Published | Updated

Agentic AI in Pharma: Drug Discovery and Content
14:57

Key takeaway

  • How agentic AI in pharma supports drug discovery and regulatory content, what FDA and EMA have said, and how to govern and adopt agents safely.

Agentic AI in pharma means software agents that plan and carry out multi-step work, such as screening a target, assembling a regulatory document or checking a safety report, while people keep the decisions that carry scientific or legal weight. It fits best where the work is long, document-heavy and rule-bound: early drug discovery, clinical and regulatory content, and pharmacovigilance. It fits poorly where a single error cannot be caught before it reaches a patient or a regulator.

This guide is written for pharma CIOs, Chief AI Officers, heads of R&D and regulatory IT, and enterprise architects. It covers where agents help in drug discovery and content management, what regulators have said so far, how to govern agents, and a sequence for adopting them. For the wider clinical picture, see our guide to agentic AI in healthcare systems, and for the supply side, AI in the biopharmaceutical supply chain.

What is agentic AI in pharma and how does it differ from earlier AI?

Earlier pharma AI mostly answered one question at a time: predict a property, classify a document, rank a list. Agentic AI adds a loop. An agent is given a goal, breaks it into steps, calls tools and data sources, checks the result and decides what to do next, within limits set by people. In a regulated setting the limits matter more than the autonomy: which systems the agent may read, what it may write, and which steps need a named human to approve.

ApproachWhat it doesWhere it fits in pharmaMain limit
Predictive modelScores or classifies one inputProperty prediction, document classificationNeeds a person to chain the steps
Generative assistantDrafts text or structures on requestFirst drafts of summaries and sectionsNo plan, no tool use, no memory of the task
Agent with toolsPlans, calls systems, checks results, escalatesLiterature review, screening workflows, document assembly, case triageNeeds access controls, logging and validation

Where does agentic AI fit in drug discovery?

Drug discovery is long, costly and high-risk, and much of it is repeated analysis across many data sources. That is where agents can take on work. The table maps each stage to the agent task, the decision a scientist keeps, and the strength of public evidence.

Two-column diagram: agent tasks (rank targets, screen compounds, draft regulatory text, watch for changes) paired with the human control for each (scientist, chemist, reviewer, regulatory affairs).
StageWhat an agent can doWhat a scientist still decidesEvidence status
Target identificationReads literature, omics and public databases; ranks candidate targets with the evidence behind eachWhether a target is biologically credible and worth fundingPublished case: a generative AI approach identified TNIK as a target in idiopathic pulmonary fibrosis (see below)
Compound screening and designRuns virtual screening and generative design tools, filters candidates, suggests molecules to synthesiseWhich molecules are synthesised and testedCompany-reported speed gains; independent comparison data is limited
Modelling and simulationSets parameters, reruns simulations, flags results that disagree with assay dataWhether a model is valid for the question being askedDepends on the model and the data; validate per use
Workflow orchestrationRaises requests to labs, tracks tests, assembles the evidence pack for a candidateApprovals, budget and prioritiesOperational, low scientific risk when logged
Clinical trial supportProposes cohort criteria, flags enrolment risks, drafts protocol sections for reviewProtocol design, eligibility and any change to a running trialRegulated; follow the sponsor and regulator rules for the use

What has one AI-designed drug shown so far?

The best-documented public case is Insilico Medicine's rentosertib (ISM001-055), a small-molecule TNIK inhibitor for idiopathic pulmonary fibrosis. A Phase IIa trial (GENESIS-IPF) in 71 patients at 22 sites in China, published in Nature Medicine on 3 June 2025, reported a mean forced vital capacity gain of 98.4 mL in the 60 mg once-daily group against a mean decline of 20.3 mL on placebo over 12 weeks. The company also states that its 22 candidates nominated between 2021 and 2024 took 12 to 18 months on average from project start to preclinical candidate nomination, against a typical 2.5 to 4 years. Those timing figures are the company's own, as reported in its press release. The trial was small and short, so it is early evidence, not proof of approval. Source: EurekAlert news release.

How does agentic AI help with regulatory and medical content?

Pharma companies maintain regulatory submissions, clinical study reports, standard operating procedures (SOPs), labelling, medical information responses and promotional material. Each has to be accurate, consistent and traceable to a source. Agents can do the assembly and checking work, with reviewers approving what is released. Governed retrieval matters here: AgentSearch is ElixirData's context-aware enterprise search across unstructured knowledge bases, which respects access rules and runs under Context OS governance.

Content taskWhat the agent doesHuman controlRisk if unchecked
First drafts of regulatory sectionsPulls approved data and prior text into a template and cites each sourceAuthors and regulatory leads review and sign offUnsupported statements enter a submission
Consistency checksCompares terminology, claims and numbers across documentsReviewer resolves each flagged differenceFalse positives waste time; missed conflicts persist
Change monitoringWatches regulator and publication feeds and lists documents that may need updatesRegulatory affairs decides what to changeActing on a misread update
Knowledge retrievalFinds related studies, trial data and past agency feedback and summarises with citationsScientist checks the cited passagesAnswers without a source
LocalisationPrepares translations that keep approved termsLocal reviewers approve before useMeaning drift in safety-critical text

For compliance evidence across these workflows, AgentGRC keeps autonomous actions inside policy and records evidence that audit and risk teams can review.

What have regulators said about AI in the medicines lifecycle?

Guidance is still taking shape, and parts of it are drafts. Check each source for the latest status before relying on it.

SourceWhat it saysStatus (as read 12 Nov 2026)Why it matters for agents
FDA, Considerations for the Use of AI to Support Regulatory Decision-Making for Drug and Biological ProductsSets out a risk-based credibility assessment framework for AI models used for a particular context of useDraft guidance, January 2025; non-binding recommendationsDefine the context of use for each agent and evidence its credibility for that use
EMA, Reflection paper on the use of AI in the medicinal product lifecycleCovers AI and machine learning at any step from drug discovery to the post-authorisation setting, for human and veterinary medicinesAdopted version first published 30 September 2024A reflection paper signals expectations; it is not a licence to skip validation
21 CFR Part 11Criteria for trustworthy electronic records and signatures; section 11.10(e) calls for secure, computer-generated, time-stamped audit trailsIn forceAgent actions that create or change regulated records need audit trails and validated systems

What are the governance, security and cost risks?

How do we keep agent actions auditable?

Log every agent step: the goal, the data read, the tool called, the output and the human who approved it. Version the policies and prompts the agent runs under, so a past decision can be reconstructed. ElixirData Context OS keeps governed context, versioned policy and decision traces in one decision layer above AI agents, which suits this need.

What data problems break agents?

Agents are only as reliable as the data they can reach. Siloed systems, inconsistent identifiers and uncontrolled document versions produce confident but wrong outputs. Fix the source of truth for each content type before giving an agent write access.

How should patient and research data be protected?

Give each agent the least access it needs, separate research data from patient data, and apply the data protection law that governs the records involved, such as GDPR where personal data of people in the EU is processed. Treat prompts and outputs as records that can contain sensitive data.

What drives cost?

The visible cost is model and tooling spend. The larger costs are usually validation effort, integration with document and laboratory systems, and reviewer time. Budget for them from the start, and measure reviewer time saved, not drafts produced.

When should pharma teams not use agents?

SituationWhy to hold backSafer option
Final decisions on safety, dosing or eligibilityAn error can reach patients and cannot be caught laterUse an agent to prepare evidence, with a qualified person deciding
Regulated records with no audit trail in the toolchainPart 11 style controls cannot be shownFix logging and validation first
Data that is incomplete or ungovernedOutputs cannot be trusted or tracedClean and catalogue the data, then pilot
Tasks that run well as a fixed scriptAn agent adds variability without benefitKeep deterministic automation

How should a pharma team sequence adoption?

  1. Choose one read-only workflow. Literature review or document consistency checking is a sensible start, because the agent only reads and reports.

  2. Define the context of use. Write down the question the agent answers, the data it may read and the decision it must never make.

  3. Add logging and policy. Record every step and put approval gates on any write action.

  4. Validate against expert work. Compare agent outputs with those of qualified staff on a fixed test set before wider use.

  5. Extend to drafting and orchestration. Allow draft creation and task routing once review time and error rates are measured.

  6. Review regulatory status each quarter. FDA and EMA material is changing, so recheck the draft and adopted documents.

Teams working in this area also raise safety signal detection and clinical trial intelligence as use cases. Both depend on the same controls: governed data access, evidence for each flag and a qualified reviewer. Our overview of autonomous operations in healthcare covers the operating model.

What is likely to change next?

Two things are worth watching. First, whether FDA finalises its draft credibility framework, since it is the most detailed statement so far on evidencing an AI model for a specific context of use. Second, how EMA and national agencies apply their AI principles in day-to-day reviews. Neither is settled in the documents read for this guide, so plan for change and keep agent designs modular.

To map one pharma decision your agents should make, and the context and policy it depends on, book a Context Workshop. See what happens in the workshop.

FAQ

What is agentic AI in the pharmaceutical industry?

Agentic AI in pharma uses software agents that plan and carry out multi-step tasks, such as literature review, document assembly or case triage, using approved tools and data, with people approving decisions that carry scientific or legal weight.

Has an AI-designed drug reached clinical trials?

Yes. Insilico Medicine's rentosertib, a TNIK inhibitor for idiopathic pulmonary fibrosis, reported Phase IIa results in Nature Medicine on 3 June 2025 from a 71-patient trial. It is early evidence, and the trial was small and lasted 12 weeks.

Does FDA have guidance on AI in drug development?

FDA published draft guidance in January 2025 on using AI to support regulatory decision-making for drugs and biological products. It proposes a risk-based credibility assessment for a defined context of use and is non-binding. Check the FDA page for later changes.

What has EMA said about AI?

EMA's reflection paper on AI in the medicinal product lifecycle covers AI and machine learning from drug discovery to the post-authorisation setting. The adopted version was first published on 30 September 2024.

What controls do agents need in regulated pharma work?

At minimum, least-privilege access, logged and time-stamped actions, versioned policies, human approval for write actions and validation against expert work. 21 CFR Part 11 section 11.10(e) calls for secure, computer-generated, time-stamped audit trails for regulated electronic records.

Next Steps to Implement Agentic AI in Pharmaceutical Industry

Leverage the power of Agentic AI to transform pharmaceutical operations, from drug discovery to supply chain optimization. Our experts can guide you in integrating Agentic workflow and Decision Intelligence to enhance research, clinical trials, and regulatory compliance.

Follow XenonStack on LinkedIn: XenonStack on LinkedIn for new guides on agentic AI, data and platform engineering.

Ready to put AI agents to work? Explore ElixirClaw, the agentic OS platform to build, orchestrate and govern AI agents.

Table of Contents

navdeep-singh-gill

Navdeep Singh Gill

Global CEO and Founder of XenonStack

LinkedIn profile

Navdeep Singh Gill is serving as Chief Executive Officer and Product Architect at XenonStack. He holds expertise in building SaaS Platform for Decentralised Big Data management and Governance, AI Marketplace for Operationalising and Scaling. His incredible experience in AI Technologies and Big Data Engineering thrills him to write about different use cases and its approach to solutions.

Get the latest articles in your inbox

Subscribe Now

Interested in solving your challenges with the XenonStack team?
Get Started

Tell us about you and your priorities so we can prepare the right conversation. It takes about 2 minutes.

Please Select your Industry
Banking
Fintech
Payment Providers
Wealth Management
Discrete Manufacturing
Semiconductor
Machinery Manufacturing / Automation
Appliances / Electrical / Electronics
Elevator Manufacturing
Defense & Space Manufacturing
Computers & Electronics / Industrial Machinery
Motor Vehicle Manufacturing
Food and Beverages
Distillery & Wines
Beverages
Shipping
Logistics
Mobility (EV / Public Transport)
Energy & Utilities
Hospitality
Digital Gaming Platforms
SportsTech with AI
Public Safety - Explosives
Public Safety - Firefighting
Public Safety - Surveillance
Public Safety - Others
Media Platforms
City Operations
Airlines & Aviation
Defense Warfare & Drones
Robotics Engineering
Drones Manufacturing
AI Labs for Colleges
AI MSP / Quantum / AGI Institutes
Retail Apparel and Fashion

Continue